Information  X 
Enter a valid email address

Company Name matching 'LIDDS AB'

Date
Time Source
Company
Announcement
14 Jan 2022 1:00 pm GNW   LIDDS AB LIDDS presents at Redeye Fight Cancer Seminar
11 Jan 2022 4:00 pm GNW   LIDDS AB LIDDS announces successful stage 1 in R&D project
29 Dec 2021 9:00 am GNW   LIDDS AB LIDDS announces positive topline results from the phase I dose-escalating study of NanoZolid®-formulated docetaxel
20 Dec 2021 2:00 pm GNW   LIDDS AB LIDDS Announces Appointment of Matthew Lindon as Chief Scientific Officer
17 Dec 2021 8:30 am GNW   LIDDS AB LIDDS patent covering the NanoZolid® production process granted in China
22 Nov 2021 3:45 pm GNW   LIDDS AB LIDDS Interim report January – September 2021
17 Nov 2021 9:00 am GNW   LIDDS AB Nomination Committee appointed for the Annual General Meeting 2022 in LIDDS
15 Nov 2021 10:00 am GNW   LIDDS AB LIDDS Announces Appointment of Johan Harmenberg as Chief Medical Officer
04 Oct 2021 6:30 pm GNW   LIDDS AB NanoZolid®-formulated Docetaxel is Safe and Tolerable Showing Signs of Clinical Efficacy
28 Sep 2021 3:00 pm GNW   LIDDS AB LIDDS patent covering the NanoZolid® production process granted in Russia and Australia
06 Jul 2021 1:00 pm GNW   LIDDS AB LIDDS – subscription of warrants
28 May 2021 7:45 am GNW   LIDDS AB LIDDS new CEO will present at Redeye’s Growth Day and Aktiespararna’s Småbolagsdagarna
16 Apr 2021 8:00 am GNW   LIDDS AB Prostate cancer study to be initiated at Uppsala University Hospital with NanoZolid technology®
08 Apr 2021 7:30 am GNW   LIDDS AB International Journal of Pharmaceutics Publishes Study on the NanoZolid® Technology for Local Release of Biomolecules
31 Mar 2021 10:00 am GNW   LIDDS AB LIDDS CEO Interview with Finwire TV and Updated Company Presentation
29 Mar 2021 7:45 am GNW   LIDDS AB NanoZolid® Technology Patent Portfolio Approved World Wide
25 Feb 2021 7:30 am GNW   LIDDS AB LIDDS and Pharmidea signs manufacturing agreement
24 Feb 2021 4:19 pm GNW   LIDDS AB LIDDS files patent application for method to treat brain cancer with intratumoral depot injections
04 Feb 2021 9:00 am GNW   LIDDS AB European Urology Focus has accepted a scientific article describing LIDDS Phase IIb study results with Liproca® Depot
22 Dec 2020 7:45 am GNW   LIDDS AB LIDDS has decided to apply for listing of the company’s shares on Nasdaq Stockholm Main Market in 2021
18 Dec 2020 7:30 am GNW   LIDDS AB Update on Chinese Conditional Market Approval (CMA) for Liproca® Depot
18 Nov 2020 2:15 pm GNW   LIDDS AB A review article defines LIDDS as a key player in TLR9 agonist research field and being the only provider having a sustained release product in development
19 Oct 2020 8:30 am GNW   LIDDS AB LIDDS announces outcome of subscription of shares in the incentive programs 2017/2020
05 Mar 2020 7:30 am GNW   LIDDS AB LIDDS will participate in Redeye’s Fight Cancer Seminar on March 10
14 Jan 2020 7:45 am GNW   LIDDS AB LIDDS: The United States Patent and Trademark Office has registered the LIDDS trademark NANOZOLID in the US
13 Jan 2020 2:15 pm GNW   LIDDS AB LIDDS: Stockpicker´s buy recommendation for 2020 picks LIDDS share as one of twelve attractive Swedish companies
10 Dec 2019 7:30 am GNW   LIDDS AB LIDDS: Update of News Release sent on November 9, 2019, with PDF-file: New Company Update and Market Valuation from Redeye
09 Dec 2019 1:30 pm GNW   LIDDS AB LIDDS: New Company Update and Market Valuation from Redeye
02 Dec 2019 10:15 am GNW   LIDDS AB LIDDS Interview with the LPC-004 study investigator, Professor Laurence Klotz, about the LIDDS Liproca® Depot Phase IIb study results
16 Nov 2019 9:10 am GNW   LIDDS AB LIDDS Liproca® Depot Phase IIb study results presented at EMUC19 showing both primary and secondary endpoints being met
06 Nov 2019 7:45 am GNW   LIDDS AB LIDDS adds Lithuanian clinics to phase I study
24 Sep 2019 6:00 pm GNW   LIDDS AB LIDDS: Wikow Invest is still the biggest shareholder in LIDDS (publ)
29 Aug 2019 7:40 am GNW   LIDDS AB LIDDS Delårsrapport april - juni 2019
28 Aug 2019 9:57 am GNW   LIDDS AB LIDDS: Liproca® Depot Phase IIb results to be presented as “Late Breaking News” at EMUC in Vienna on November 16, 2019


Company Announcements Archive »


a d v e r t i s e m e n t